Last reviewed · How we verify
paclitaxel, gemcitabine, and oxaliplatin
At a glance
| Generic name | paclitaxel, gemcitabine, and oxaliplatin |
|---|---|
| Sponsor | University of Southern California |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Diarrhoea
- Nausea
- Fatigue
- Vomiting
- Decreased appetite
- Anaemia
- Constipation
- Neutrophil count decreased
- Abdominal pain
- Neutropenia
- Asthenia
- Hypokalaemia
Key clinical trials
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2)
- A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer (PHASE2)
- A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer (PHASE1)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (PHASE1)
- A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: